Compare · BSX vs ICCM
BSX vs ICCM
Side-by-side comparison of Boston Scientific Corporation (BSX) and IceCure Medical Ltd. (ICCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and ICCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 17951.5x ICCM ($3.6M).
- Over the past year, BSX is down 55.3% and ICCM is down 95.7% - BSX leads by 40.4 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 2 for ICCM).
- Company
- Boston Scientific Corporation
- IceCure Medical Ltd.
- Price
- $44.38+0.50%
- $1.05+1.93%
- Market cap
- $63.97B
- $3.6M
- 1M return
- +1.88%
- -47.12%
- 1Y return
- -55.28%
- -95.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 2
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest ICCM
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Medical Receives Regulatory Approval to Market ProSense® in China
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
- West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation